Camille Chakiba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Camille Chakiba has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- Adrien Buisson
Department of Biopathology Centre Léon Bérard Lyon France
10 shared publications - Anthony Gonçalves
Department of Medical Oncology, Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
10 shared publications - Audrey Mailliez
Department of Medical Oncology, Centre Oscar Lambret, Lille, France
10 shared publications - Clara Guyonneau
20Research and Development, UNICANCER, Paris, France
10 shared publications - Elsa Curtit
11Medical Oncology Department, CHRU Besancon - Hopital Jean Minjoz, Besancon, France
10 shared publications - Etienne Brain
Department of Medical Oncology, Institut Curie, Saint-Cloud, France
10 shared publications
Latest Publications
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 3 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Details of genetic counselling recommended after NGS analysis
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 3 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Details of genetic counselling recommended after NGS analysis
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Protocol 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
EudraCT n°: 2018-003832-57 DOLAF-An international multicenter phase II trial of Durvalumab (MEDI4736) plus OLAparib plus Fulvestrant in metastatic or locally advanced ER-positive, HER2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessProtocol 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
EudraCT n°: 2018-003832-57 DOLAF-An international multicenter phase II trial of Durvalumab (MEDI4736) plus OLAparib plus Fulvestrant in metastatic or locally advanced ER-positive, HER2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Centralized panel-NGS and Tumor PD-L1 expression analysis
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Centralized panel-NGS and Tumor PD-L1 expression analysis
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Representativeness of Study Participants
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Representativeness of Study Participants
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Baseline patient and tumor characteristics in the previously documented germline BRCA mutated population
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Baseline patient and tumor characteristics in the previously documented germline BRCA mutated population
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Baseline patient and tumor characteristics (evaluable population)
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Baseline patient and tumor characteristics (evaluable population)
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Progression-free survival (2A) and overall survival (2B) according to the type of BRCA pathogenic variant (BRCA1 versus BRCA2)
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Progression-free survival (2A) and overall survival (2B) according to the type of BRCA pathogenic variant (BRCA1 versus BRCA2)
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Progression-free survival (1A) and overall survival (1B) in the population with previously documented germline BRCA pathogenic variant (Intention-To-Treat)
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Progression-free survival (1A) and overall survival (1B) in the population with previously documented germline BRCA pathogenic variant (Intention-To-Treat)
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 2 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Details on the statistical hypotheses regarding the safety run-in stage and the subgroup of patients with gBRCAm
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 2 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Details on the statistical hypotheses regarding the safety run-in stage and the subgroup of patients with gBRCAm